1.1 Controls
for the Prevention And Detection Of Fraudulent Or Abusive Practices
The contractor shall establish procedures and
utilize controls for the prevention and detection of fraudulent
or abusive patterns and trends in billings by providers, pharmacies,
entities, and beneficiaries on a pre- and postpayment basis. Controls
shall include the following (and be made available to the Defense
Health Agency (DHA) Program Integrity Office (PI)):
• Eligibility
verifications for beneficiaries and providers/pharmacies.
• Coordination of benefits.
• Prepayment edits (e.g.,
applied to program exclusions and limitations).
• Utilization of discretionary
or coordinated placement of providers/beneficiaries on prepayment
review.
• Postpayment
utilization review to detect fraud and/or abuse by either beneficiaries, pharmacies,
or providers and to establish dollar loss to the Government.
• Application of security
measures to protect against embezzlement or other dishonest acts by
employees.
• Incorporate
anti-fraud attestation language whenever/wherever practical (e.g.,
claim forms, network agreements, electronic claims submission agreements).
• Utilization of Fraudlines/Hotlines.
• Prepayment duplicate
screening.
• Postpayment
duplicate screening.
• Verification of provider
status (e.g., credentials, licensure) to include appropriate termination
action when findings/recommendations of boards, etc. results in
loss or suspension of licensure or certification.
• Program Integrity
(PI) targeted measures (e.g., prepay anti-fraud review; use of post payment
fraud detection software; routine anti-fraud data mining; investigative
anti-fraud auditing; select provider/beneficiary education).
• Specific to pharmacy,
controls include comparing reversal rates; excessive partial fill submissions;
high use patients; review of outliers; codes with medication therapy
for high ingredient costs; claims with high average ingredient cost;
review of brand/generic fill rates; top pharmacies per generic code
rate; controlled substance prescription rates; and ability to conduct
on-site audits of pharmacies who meet these indicators and ability
to review/perform on-site of top one percent of providers who meet
these indicators.